• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $MTH

    Meritage Homes Corporation

    Subscribe to $MTH
    $MTH
    Homebuilding
    Consumer Discretionary

    Meritage Homes Corporation designs and builds single-family homes in the United States. The company operates through two segments, Homebuilding and Financial Services. It acquires and develops land; and constructs, markets, and sells homes for first-time and first move-up buyers. The company also offers title insurance and closing/settlement services to its homebuyers. It builds and sells homes in Texas, Arizona, California, Colorado, Florida, North Carolina, South Carolina, Georgia, and Tennessee under the Meritage Homes brand name. Meritage Homes Corporation was founded in 1985 and is based in Scottsdale, Arizona.

    IPO Year:

    Exchange: NYSE

    Website: meritagehomes.com

    Peers

    $LGIH
    $BZH
    $DHI
    $HOV
    $KBH
    $LEN
    $MHO
    $TMHC
    $TPH

    Recent Analyst Ratings for Meritage Homes Corporation

    DatePrice TargetRatingAnalyst
    5/5/2025$82.00Buy
    BofA Securities
    3/6/2025$70.00Sell → Neutral
    Seaport Research Partners
    12/13/2024$220.00 → $197.00Overweight → Neutral
    Analyst
    11/7/2024Outperform → Mkt Perform
    Raymond James
    10/31/2024$205.00 → $235.00Neutral → Buy
    Goldman
    10/15/2024$160.00 → $195.00Underperform → Neutral
    Wedbush
    8/14/2024$230.00Peer Perform → Outperform
    Wolfe Research
    8/5/2024$153.00Neutral → Sell
    Seaport Research Partners
    7/24/2024$220.00Outperform
    Raymond James
    4/2/2024$155.00 → $148.00Neutral → Underperform
    Wedbush
    See more ratings